A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Multiple Doses of TAK-935 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Multiple Doses of TAK-935 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2017

At a glance

  • Drugs TAK 935 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 03 Dec 2017 According to an Ovid Therapeutics media release, data from this trial was presented at the American Epilepsy Society (AES) 71st Annual Meeting.
    • 21 Nov 2017 According to an Ovid Therapeutics media release, data from this trial will be presented at the American Epilepsy Society (AES) 71st Annual Meeting 2017.
    • 01 Dec 2015 Planned end date changed from 1 Jun 2016 to 1 Feb 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top